Adjuvant regimen has ‘potential’ to change practice in high-risk liver cancer

Adjuvant treatment with atezolizumab and bevacizumab extended RFS compared with active surveillance among patients with hepatocellular carcinoma, according to study findings presented at AACR Annual Meeting.The combination exhibited a generally manageable safety profile, results of the randomized phase 3 IMbrave050 trial showed.The findings suggest the combination could be a new standard for adjuvant treatment of HCC, researchers concluded.“Due to the lack of proven adjuvant therapy strategies for HCC, patients who are treated with surgical resection or thermal ablation with curativeRead More